PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Jan 24, 2014
SOUTH PLAINFIELD, NJ – January 24, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT) (PTC) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Company's marketing authorization application (MAA) for conditional approval of ataluren for ...
Jan 24, 2014
SOUTH PLAINFIELD, NJ – January 24, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced an expansion of its senior management team with the appointment of Robert J. Spiegel M.D., FACP to Chief Medical Officer and Murad Husain to Vice President, Global Regulatory Affairs. PTC also announced the promotions of Joseph Colacino, Ph.D. ...
Jan 22, 2014
SOUTH PLAINFIELD, NJ, JANUARY 22, 2014 - PTC Therapeutics, Inc. (NASDAQ: PTCT), the SMA Foundation, and Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that their joint research program in Spinal Muscular Atrophy (SMA) has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy vol...
Jan 6, 2014
SOUTH PLAINFIELD, NJ – January 6, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 2014 J.P. Morgan Healthcare Conference on Monday, January 13 at 3:00 pm PT.The presentation will be webcast live on the Events and Presentations page under the investor relation...
Dec 23, 2013
SOUTH PLAINFIELD, NJ – December 23, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI), effective prior to the market open today. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securi...
Dec 12, 2013
South Plainfield, NJ – December 12, 2013 – PTC Therapeutics, Inc.,(NASDAQ: PTCT) today announced the publication of data in PLOS ONE demonstrating that nonsense mutation Duchenne muscular dystrophy (nmDMD) patients treated with ataluren, an investigational new drug, experienced an increase in dystrophin expression. These data were obtaine...
Nov 14, 2013
SOUTH PLAINFIELD, NJ - November 14, 2013 - PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes, today announced financial and corporate results for the quarter ended September ...
Nov 7, 2013
SOUTH PLAINFIELD, NJ – November 7, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that PTC management will host a webcast conference call to discuss financial results for the third quarter ended September 30, 2013 and provide a corporate update on Thursday, November 14, 2013 at 8:00 a.m. (ET) before the opening of the market...
Nov 5, 2013
SOUTH PLAINFIELD, NJ – NOVEMBER 5, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2013 Credit Suisse Annual Health Care Conference on Tuesday, November 12 at 4:30 pm ET. The presentation will be webcast live on the Events and Presentations page unde...
Oct 18, 2013
PTC THERAPEUTICS TO SHOWCASE BREADTH OF PIPELINE AT UPCOMING R&D DAYSOUTH PLAINFIELD, NJ – October 18, 2013 – PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it will hold its first R&D Day on Friday, October 25, 2013 from 8:30 a.m. to 12:00 p.m. ET at the Four Seasons Hotel in New York City. Members of PTC's senior ...
Page: FirstPrevious ...
21
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue